SARAH KASSIN: Open Payments
NPI 1205484219 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 66 payments from 10 companies in 2025. Trend: 2023 $1,305 · 2024 $1,244 · 2025 $1,209
Food & beverage: $1,209
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $278 |
| Alkermes, Inc. | 14 | $192 |
| Lundbeck LLC | 8 | $184 |
| Vanda Pharmaceuticals Inc. | 9 | $175 |
| ABBVIE INC. | 10 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $130 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: REXULTI, ARISTADA, VRAYLAR, HETLIOZ, CAPLYTA, ABILIFY MAINTENA, AUSTEDO XR, FANAPT.
Industry payments across KS — which companies pay providers there.
